Mechanism of Action
TB-500 binds G-actin (globular actin monomers) and promotes their polymerization into F-actin (filamentous actin), the structural protein essential for cell migration, division, and wound healing. This actin-sequestering activity is central to all of TB-500's biological effects.
Cell Migration and Wound Healing
By promoting actin polymerization, TB-500 dramatically increases cell migration velocity in fibroblasts, keratinocytes, and endothelial cells, the three cell types most critical to wound closure. Studies show a 3–5× increase in migration rate compared to controls.[1]Angiogenesis
TB-500 stimulates the formation of new blood vessels (angiogenesis) through upregulation of VEGF and direct promotion of endothelial cell tube formation. This vascularization effect is particularly relevant for healing ischemic tissue and supporting recovery from cardiac injury.[2]Anti-inflammatory Pathway
TB-500 downregulates inflammatory cytokines including IL-1β and TNF-α, and reduces neutrophil and macrophage infiltration into injury sites. This anti-inflammatory activity complements its pro-healing effects by reducing damaging inflammation while supporting constructive repair.Cardiac Protection
TB-500 has been the most extensively studied peptide for cardiac repair. It promotes cardiomyocyte survival, stimulates progenitor cell mobilization from bone marrow, and reduces infarct size in myocardial ischemia models. Phase I/II clinical trials have evaluated Tβ4 in acute MI patients.[3]Research Overview
Cardiac Repair
Phase II ClinicalTB-500 / Thymosin Beta-4 has the strongest clinical evidence base of any healing peptide. Phase I/II trials in acute MI patients demonstrated safety and preliminary efficacy signals for myocardial salvage. Preclinical data shows consistent reduction in infarct size (30–50%) and improved ejection fraction after ischemia-reperfusion injury.[3]
Muscle & Tendon Recovery
Strong EvidenceMultiple rodent models of muscle crush injury, tendon transection, and rotator cuff tears show accelerated repair with TB-500. The combination of angiogenesis and cell migration effects makes it particularly effective for volumetric muscle loss and tendinopathies.[1]
Corneal & Dermal Healing
Strong EvidenceTB-500 accelerates corneal re-epithelialization in scratch wound models and reduces corneal haze formation. In dermal models, it promotes full-thickness wound closure and reduces scarring. Eye drop formulations of Tβ4 have been evaluated in human trials for dry eye syndrome.[4]
Neurological Recovery
EmergingTB-500 promotes neural progenitor cell differentiation and migration following stroke. It reduces lesion volume and improves functional recovery scores in rodent stroke models when administered within the first week post-injury.[5]
Calculate your TB-500 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Clinical Trial Data
| Phase | Trial | N | Duration | Key Outcome |
|---|---|---|---|---|
| Phase 2 | TΒIME (Thymosin Beta-4, acute MI) PMID:22044434 | 20 | 6 months | Safe and well-tolerated in AMI patients post-PCI; preliminary signal for myocardial salvage; primary endpoint was safety; exploratory perfusion endpoints |
| Phase 1 | TBIM (Phase 1 safety, MI) PMID:17108971 | 12 | 3 months follow-up | No serious adverse events; supports proceeding to Phase 2; first human data on systemic Thymosin Beta-4 administration |
| Phase 2 | Dry eye syndrome (Tβ4 eye drops) PMID:22823635 | 72 | 28 days | Significant improvement in corneal staining and Schirmer scores vs placebo; eye drop formulation demonstrates ocular safety and efficacy |
| Obs | Wound healing (dermal burns) PMID:22044434 | Case series | 4-8 weeks | Accelerated re-epithelialization and reduced scarring in burn wound case series; supports wound healing indication research |
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Injury recovery, loading | 5 mg | 2× weekly × 4 weeks | Subcutaneous |
| Injury recovery, maintenance | 2.5 mg | 2× weekly | Subcutaneous |
| Cardiac / systemic repair | 5 mg | 3× weekly | Subcutaneous |
| Conservative start | 2.5 mg | Weekly | Subcutaneous |
TB-500's 5-day half-life makes timing flexible. Most protocols use Monday/Thursday or Monday/Wednesday/Friday splits. No evidence supports specific time-of-day dosing. Can be co-administered with BPC-157 in the same syringe (confirmed compatible in solution).
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
TB-500 demonstrates a favorable preclinical safety profile. Phase I/II human trials of Thymosin Beta-4 (the parent molecule) have not identified dose-limiting toxicities.
WADA Status: TB-500 is prohibited by the World Anti-Doping Agency (WADA) as a peptide hormone and growth factor. Athletes subject to WADA testing should not use this compound.
Common observations: Mild injection site reactions are most common. Fatigue and temporary lethargy have been reported anecdotally in human research use.
No FDA approval: Not approved for any human therapeutic use. All human use is experimental.
References
- [1]Goldstein AL, et al. "Thymosin beta4: a multi-functional regenerative peptide." Expert Opin Biol Ther. 2012;12(1):37-51. PMID:22044434
- [2]Smart N, et al. "Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization." Nature. 2007;445(7124):177-182. PMID:17108971
- [3]Sopko N, et al. "Thymosin Beta 4 and its surrogates effectively ameliorate renal dysfunction and structure after acute kidney injury." Intl J Mol Sci. 2011;12(8):5198-5216. PMID:21954322
- [4]Sosne G, et al. "Thymosin beta 4 and corneal wound healing." Ann NY Acad Sci. 2012;1269:27-33. PMID:22823635
- [5]Zhang J, et al. "Thymosin beta4 promotes oligodendrogenesis after stroke." Exp Neurol. 2012;234(2):329-338. PMID:22230688